EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Direct oral anticoagulants in very elderly and high-bleeding-risk patients with atrial fibrillation often excluded from oral anticoagulation therapy: a nationwide population-based cohort study

Young-Hae Go iD, So-Ryoung Lee iD, Eue-Keun Choi iD, Hyo-Jeong Ahn iD, Kyung-Do Han iD, Seil Oh iD, Gregory Y H Lip iD

Europace · 07.10.2025 · 27 (10)

DOI: 10.1093/europace/euaf230 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Europace, online erschienen am 29.09.2025. Verfasst von Young-Hae Go und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea. Hauptthemen laut MEDLINE: Atrial Fibrillation, Hemorrhage, Anticoagulants, Factor Xa Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Patient-Centered Clinical Research Coordinating Center, PACEN, Ministry of Health & Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

In the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) trial, very low-dose edoxaban (15 mg once daily) showed better efficacy and positive net clinical benefit compared with placebo in very elderly, high-bleeding-risk patients with atrial fibrillation (AF). However, there are limited data to generalize these results into daily practice. We aimed to investigate the optimal oral anticoagulant (OAC) strategy for the best net clinical benefit in ELDERCARE-AF-like patients. Methods and results We used the Korean nationwide claims database to identify AF patients aged ≥80 years from 2014 to 2017 who had one or more ELDERCARE-AF trial inclusion criteria. The risks of ischaemic stroke, major bleeding, all-cause death, and net clinical outcome were evaluated. Primarily, we compared patients without OAC therapy (non-OAC group) to patients with direct OAC (DOAC) therapy (DOAC group), using a propensity score weighting method. A total of 23 858 patients were included (no OAC: 16 575; warfarin: 2390; DOAC: 4893). Among the DOAC group, 69% used low dose, and 9% used very low dose. Compared with the non-OAC group, the DOAC group showed lower risks of ischaemic stroke (hazard ratio, 95% confidence interval: 0.81, 0.68–0.96) and all-cause death (0.91, 0.86–0.96) and a higher risk of major bleeding (1.44, 1.21–1.70). The DOAC group was associated with a lower risk of net clinical outcome compared with the non-OAC group (0.93, 0.88–0.98).

Conclusion

In very elderly, high-bleeding-risk patients with AF, DOACs that were prescribed in usual clinical practice showed better effectiveness and positive net clinical benefit compared with no OAC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationHemorrhageAnticoagulantsFactor Xa InhibitorsIschemic StrokeThiazolesPyridinesHumansAged, 80 and overMaleFemaleAdministration, OralRepublic of KoreaRisk AssessmentRisk FactorsTreatment OutcomeAge Factors

Stichwörter der Autor:innen

Atrial fibrillationBleedingDirect oral anticoagulantStrokeVery elderly

Substanzen

AnticoagulantsedoxabanFactor Xa InhibitorsThiazolesPyridines

Autor:innen und Institutionen

  • Department of Internal Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea.
  • Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea.
  • Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea.
  • Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Chest and Heart Hospital, Liverpool, UK.
  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

ORCID-Profile: Young-Hae Go, So-Ryoung Lee, Eue-Keun Choi, Hyo-Jeong Ahn, Kyung-Do Han, Seil Oh, Gregory Y H Lip

Förderung

  • Patient-Centered Clinical Research Coordinating Center
  • PACEN
  • Ministry of Health & Welfare
  • National Research Foundation of Korea
  • NRF
  • Korea government

Zitieren

APA

Go, Y. H., Lee, S. R., Choi, E. K., Ahn, H. J., Han, K. D., Oh, S., & Lip, G. Y. H. (2025). Direct oral anticoagulants in very elderly and high-bleeding-risk patients with atrial fibrillation often excluded from oral anticoagulation therapy: a nationwide population-based cohort study. Europace, 27(10). https://doi.org/10.1093/europace/euaf230

Vancouver

Go YH, Lee SR, Choi EK, Ahn HJ, Han KD, Oh S, et al. Direct oral anticoagulants in very elderly and high-bleeding-risk patients with atrial fibrillation often excluded from oral anticoagulation therapy: a nationwide population-based cohort study. Europace. 2025;27(10). doi:10.1093/europace/euaf230

BibTeX
@article{Go2025,
  author = {Go, Young-Hae and Lee, So-Ryoung and Choi, Eue-Keun and Ahn, Hyo-Jeong and Han, Kyung-Do and Oh, Seil and Lip, Gregory Y H},
  title = {Direct oral anticoagulants in very elderly and high-bleeding-risk patients with atrial fibrillation often excluded from oral anticoagulation therapy: a nationwide population-based cohort study},
  journal = {Europace},
  year = {2025},
  volume = {27},
  number = {10},
  doi = {10.1093/europace/euaf230}
}
Kostenlos starten →